AGIOS PHARMACEUTICALS INC (AGIO) — insider trading
Health Care · NASDAQ
AGIOS PHARMACEUTICALS INC (AGIO) has 77 reported SEC Form 4 insider transactions in our data, including 9 open-market sales among the most recent 77 (latest 2026-08-04).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-08-04 | Gheuens Sarah | Officer (Chief Medical Officer) | Open-market sale | 30,000 | $30.48 | $914.4K | Form 4 |
| 2026-07-08 | Backstrom Jay T. | Director | Option exercise / conversion (derivative) | 1,447 | — | $0 | Form 4 |
| 2026-07-08 | Backstrom Jay T. | Director | Grant / award / vesting | 1,447 | — | $0 | Form 4 |
| 2026-07-01 | Gheuens Sarah | Officer (Chief Medical Officer) | Option exercise / conversion (derivative) | 8,375 | — | $0 | Form 4 |
| 2026-07-01 | Gheuens Sarah | Officer (Chief Medical Officer) | Open-market sale | 4,007 | $37.56 | $150.5K | Form 4 |
| 2026-07-01 | Gheuens Sarah | Officer (Chief Medical Officer) | Option exercise / conversion | 8,375 | — | $0 | Form 4 |
| 2026-06-18 | Backstrom Jay T. | Director | Grant / award / vesting (derivative) | 14,950 | — | $0 | Form 4 |
| 2026-06-18 | Backstrom Jay T. | Director | Grant / award / vesting (derivative) | 2,927 | — | $0 | Form 4 |
| 2026-06-18 | Milanova Tsveta | Officer (Chief Commercial Officer) | Grant / award / vesting (derivative) | 3,000 | — | $0 | Form 4 |
| 2026-06-18 | Milanova Tsveta | Officer (Chief Commercial Officer) | Option exercise / conversion (derivative) | 3,000 | — | $0 | Form 4 |
| 2026-06-18 | Jones Cecilia | Officer (Chief Financial Officer) | Grant / award / vesting (derivative) | 3,000 | — | $0 | Form 4 |
| 2026-06-18 | Jones Cecilia | Officer (Chief Financial Officer) | Option exercise / conversion (derivative) | 3,000 | — | $0 | Form 4 |
| 2026-06-18 | Gheuens Sarah | Officer (Chief Medical Officer) | Grant / award / vesting (derivative) | 3,000 | — | $0 | Form 4 |
| 2026-06-18 | Gheuens Sarah | Officer (Chief Medical Officer) | Option exercise / conversion (derivative) | 3,000 | — | $0 | Form 4 |
| 2026-06-18 | Burns James William | Officer (Chief Legal Officer) | Grant / award / vesting (derivative) | 3,000 | — | $0 | Form 4 |
| 2026-06-18 | Burns James William | Officer (Chief Legal Officer) | Option exercise / conversion (derivative) | 3,000 | — | $0 | Form 4 |
| 2026-06-18 | Goff Brian | Director, Officer (Chief Executive Officer) | Grant / award / vesting (derivative) | 39,000 | — | $0 | Form 4 |
| 2026-06-18 | Goff Brian | Director, Officer (Chief Executive Officer) | Option exercise / conversion (derivative) | 39,000 | — | $0 | Form 4 |
| 2026-06-18 | Viswanadhan Krishnan | Officer (Chief Strategy and Operations) | Grant / award / vesting (derivative) | 3,000 | — | $0 | Form 4 |
| 2026-06-18 | Viswanadhan Krishnan | Officer (Chief Strategy and Operations) | Option exercise / conversion (derivative) | 3,000 | — | $0 | Form 4 |
| 2026-06-18 | Smith Cynthia | Director | Grant / award / vesting (derivative) | 14,950 | — | $0 | Form 4 |
| 2026-06-18 | Smith Cynthia | Director | Grant / award / vesting (derivative) | 2,927 | — | $0 | Form 4 |
| 2026-06-18 | Smith Cynthia | Director | Option exercise / conversion (derivative) | 2,816 | — | $0 | Form 4 |
| 2026-06-18 | Smith Cynthia | Director | Option exercise / conversion | 2,816 | — | $0 | Form 4 |
| 2026-06-18 | Scadden David | Director | Grant / award / vesting (derivative) | 14,950 | — | $0 | Form 4 |
| 2026-06-18 | Scadden David | Director | Grant / award / vesting (derivative) | 2,927 | — | $0 | Form 4 |
| 2026-06-18 | Scadden David | Director | Option exercise / conversion (derivative) | 2,816 | — | $0 | Form 4 |
| 2026-06-18 | Scadden David | Director | Option exercise / conversion | 2,816 | — | $0 | Form 4 |
| 2026-06-18 | Owen Adams Catherine | Director | Grant / award / vesting (derivative) | 14,950 | — | $0 | Form 4 |
| 2026-06-18 | Owen Adams Catherine | Director | Grant / award / vesting (derivative) | 2,927 | — | $0 | Form 4 |
| 2026-06-18 | Owen Adams Catherine | Director | Option exercise / conversion (derivative) | 2,816 | — | $0 | Form 4 |
| 2026-06-18 | Owen Adams Catherine | Director | Option exercise / conversion | 2,816 | — | $0 | Form 4 |
| 2026-06-18 | Ho Maykin | Director | Grant / award / vesting (derivative) | 14,950 | — | $0 | Form 4 |
| 2026-06-18 | Ho Maykin | Director | Grant / award / vesting (derivative) | 2,927 | — | $0 | Form 4 |
| 2026-06-18 | Ho Maykin | Director | Option exercise / conversion (derivative) | 2,816 | — | $0 | Form 4 |
| 2026-06-18 | Ho Maykin | Director | Option exercise / conversion | 2,816 | — | $0 | Form 4 |
| 2026-06-18 | FOUSE JACQUALYN A | Director | Grant / award / vesting (derivative) | 14,950 | — | $0 | Form 4 |
| 2026-06-18 | FOUSE JACQUALYN A | Director | Grant / award / vesting (derivative) | 2,927 | — | $0 | Form 4 |
| 2026-06-18 | FOUSE JACQUALYN A | Director | Option exercise / conversion (derivative) | 2,816 | — | $0 | Form 4 |
| 2026-06-18 | FOUSE JACQUALYN A | Director | Option exercise / conversion | 2,816 | — | $0 | Form 4 |
| 2026-06-18 | Foster-Cheek Kaye I | Director | Grant / award / vesting (derivative) | 14,950 | — | $0 | Form 4 |
| 2026-06-18 | Foster-Cheek Kaye I | Director | Grant / award / vesting (derivative) | 2,927 | — | $0 | Form 4 |
| 2026-06-18 | Foster-Cheek Kaye I | Director | Option exercise / conversion (derivative) | 2,816 | — | $0 | Form 4 |
| 2026-06-18 | Foster-Cheek Kaye I | Director | Option exercise / conversion | 2,816 | — | $0 | Form 4 |
| 2026-06-18 | CAPELLO JEFFREY D | Director | Grant / award / vesting (derivative) | 14,950 | — | $0 | Form 4 |
| 2026-06-18 | CAPELLO JEFFREY D | Director | Grant / award / vesting (derivative) | 2,927 | — | $0 | Form 4 |
| 2026-06-18 | CAPELLO JEFFREY D | Director | Option exercise / conversion (derivative) | 2,816 | — | $0 | Form 4 |
| 2026-06-18 | CAPELLO JEFFREY D | Director | Option exercise / conversion | 2,816 | — | $0 | Form 4 |
| 2026-06-18 | Ballal Rahul D. | Director | Grant / award / vesting (derivative) | 14,950 | — | $0 | Form 4 |
| 2026-06-18 | Ballal Rahul D. | Director | Grant / award / vesting (derivative) | 2,927 | — | $0 | Form 4 |
| 2026-06-18 | Ballal Rahul D. | Director | Option exercise / conversion (derivative) | 2,816 | — | $0 | Form 4 |
| 2026-06-18 | Ballal Rahul D. | Director | Option exercise / conversion | 2,816 | — | $0 | Form 4 |
| 2026-06-13 | CAPELLO JEFFREY D | Director | Option exercise / conversion (derivative) | 1,976 | — | $0 | Form 4 |
| 2026-06-13 | CAPELLO JEFFREY D | Director | Option exercise / conversion | 1,976 | — | $0 | Form 4 |
| 2026-06-13 | Owen Adams Catherine | Director | Option exercise / conversion (derivative) | 1,976 | — | $0 | Form 4 |
| 2026-06-13 | Owen Adams Catherine | Director | Option exercise / conversion | 1,976 | — | $0 | Form 4 |
| 2026-04-02 | Goff Brian | Director, Officer (Chief Executive Officer) | Option exercise / conversion (derivative) | 13,500 | — | $0 | Form 4 |
| 2026-04-02 | Goff Brian | Director, Officer (Chief Executive Officer) | Option exercise / conversion (derivative) | 25,528 | — | $0 | Form 4 |
| 2026-04-02 | Goff Brian | Director, Officer (Chief Executive Officer) | Open-market sale | 6,596 | $34.71 | $228.9K | Form 4 |
| 2026-04-02 | Goff Brian | Director, Officer (Chief Executive Officer) | Option exercise / conversion | 13,500 | — | $0 | Form 4 |
| 2026-04-02 | Goff Brian | Director, Officer (Chief Executive Officer) | Open-market sale | 12,472 | $34.71 | $432.9K | Form 4 |
| 2026-04-02 | Goff Brian | Director, Officer (Chief Executive Officer) | Option exercise / conversion | 25,528 | — | $0 | Form 4 |
| 2026-04-02 | Viswanadhan Krishnan | Officer (Chief Corp Dev & Strategy) | Option exercise / conversion (derivative) | 8,100 | — | $0 | Form 4 |
| 2026-04-02 | Viswanadhan Krishnan | Officer (Chief Corp Dev & Strategy) | Open-market sale | 2,959 | $34.71 | $102.7K | Form 4 |
| 2026-04-02 | Viswanadhan Krishnan | Officer (Chief Corp Dev & Strategy) | Option exercise / conversion | 8,100 | — | $0 | Form 4 |
| 2026-04-02 | Milanova Tsveta | Officer (Chief Commercial Officer) | Option exercise / conversion (derivative) | 8,500 | — | $0 | Form 4 |
| 2026-04-02 | Milanova Tsveta | Officer (Chief Commercial Officer) | Open-market sale | 3,262 | $34.71 | $113.2K | Form 4 |
| 2026-04-02 | Milanova Tsveta | Officer (Chief Commercial Officer) | Option exercise / conversion | 8,500 | — | $0 | Form 4 |
| 2026-04-02 | Jones Cecilia | Officer (Chief Financial Officer) | Option exercise / conversion (derivative) | 8,500 | — | $0 | Form 4 |
| 2026-04-02 | Jones Cecilia | Officer (Chief Financial Officer) | Open-market sale | 3,141 | $34.71 | $109.0K | Form 4 |
| 2026-04-02 | Jones Cecilia | Officer (Chief Financial Officer) | Option exercise / conversion | 8,500 | — | $0 | Form 4 |
| 2026-04-02 | Gheuens Sarah | Officer (Chief Medical Officer) | Option exercise / conversion (derivative) | 8,500 | — | $0 | Form 4 |
| 2026-04-02 | Gheuens Sarah | Officer (Chief Medical Officer) | Open-market sale | 2,940 | $34.71 | $102.0K | Form 4 |
| 2026-04-02 | Gheuens Sarah | Officer (Chief Medical Officer) | Option exercise / conversion | 8,500 | — | $0 | Form 4 |
| 2026-04-02 | Burns James William | Officer (Chief Legal Officer) | Option exercise / conversion (derivative) | 8,500 | — | $0 | Form 4 |
| 2026-04-02 | Burns James William | Officer (Chief Legal Officer) | Open-market sale | 3,280 | $34.71 | $113.8K | Form 4 |
| 2026-04-02 | Burns James William | Officer (Chief Legal Officer) | Option exercise / conversion | 8,500 | — | $0 | Form 4 |
Ask the chat about AGIO's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: AGIOS PHARMACEUTICALS INC (AGIO).
Last updated 2026-08-04 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.